GlassScriptPhysician profile
Johan Van Jaarsveld
NPI 1396024980
$1,151.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $377 · 2021: $263 · 2022: $341.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $305.85 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $280.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $226.59 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.39 | 2020-2022 | |
| Advanced Respiratory, INC | $54.31 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $40.00 | 2021-2022 | |
| Insmed, INC. | $32.48 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $28.69 | 2022 | |
| Philips North America LLC | $27.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.49 | 2022 | |
| United Therapeutics Corporation | $18.11 | 2021 | |
| Eisai INC. | $16.92 | 2021 | |
| Mylan Specialty L.P. | $12.59 | 2019 | |
| Genzyme Corporation | $11.08 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johan Van Jaarsveld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.